YMAB241220P30000
- 0.00
- 0.000.00%
Y-mAbs Therapeutics Newsroom
Oppenheimer Initiates Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Announces Target Price $23
Oppenheimer Initiates Coverage On Y-mAbs Therapeutics With Outperform Rating, Announces Price Target of $23
Y-mAbs Therapeutics Analyst Ratings
H.C. Wainwright Maintains Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Maintains Target Price $22
JonesTrading Maintains Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Maintains Target Price $23
Morgan Stanley Maintains Y-mAbs Therapeutics(YMAB.US) With Sell Rating, Maintains Target Price $11
Truist Financial Maintains Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Announces Target Price $21
Truist Financial Remains a Buy on Y-Mabs Therapeutics (YMAB)
Y-Mabs Therapeutics: Promising Pipeline Developments and Strong Revenue Projections Justify Buy Rating
Morgan Stanley Maintains Y-mAbs Therapeutics(YMAB.US) With Sell Rating, Maintains Target Price $11
Truist Financial Maintains Y-mAbs Therapeutics(YMAB.US) With Buy Rating
JonesTrading Maintains Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Maintains Target Price $23
Truist Financial Maintains Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Maintains Target Price $21
Morgan Stanley Maintains Y-mAbs Therapeutics(YMAB.US) With Sell Rating, Maintains Target Price $11
Analysts Offer Insights on Healthcare Companies: Y-Mabs Therapeutics (YMAB), Resmed Inc CHESS Depositary Interests on a Ratio of 10 CDIs per Ord.sh (AU:RMD) and Bayer (GB:0P6S)
Y-mAbs Therapeutics Analyst Ratings
Cantor Fitzgerald Initiates Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Announces Target Price $20
CCORF Maintains Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Maintains Target Price $26
Truist Financial Maintains Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Maintains Target Price $21
A Quick Look at Today's Ratings for Y-mAbs Therapeutics(YMAB.US), With a Forecast Between $21 to $26